Vardenafil (Levitra/Staxyn) vs Alprostadil (Caverject/MUSE): Real-World Evidence Comparison

How Each Drug Works

Vardenafil and alprostadil reach the same end point (increased penile blood flow) by entirely different mechanisms, and that difference explains their distinct place in clinical practice.

Vardenafil selectively inhibits phosphodiesterase type 5 (PDE5), the enzyme that breaks down cyclic GMP in smooth muscle. Because the drug depends on intact nitric-oxide signaling to produce cGMP in the first place, it requires at least partial neurological function and some level of sexual stimulation to generate an erection. Without that baseline signaling, the drug has little to work with.

Alprostadil bypasses nitric oxide entirely. It binds EP2 and EP3 prostaglandin receptors on smooth-muscle cells, directly elevating intracellular cAMP, relaxing cavernosal smooth muscle, and driving inflow regardless of central nerve input. This is why alprostadil remains effective in men with severe neurogenic ED (for example, complete spinal cord injury or radical prostatectomy) where PDE5 inhibitors often fail.

PDE5 Inhibition: Vardenafil Specifics

Vardenafil has a half-life of 4 to 5 hours and peak plasma concentration at roughly 60 minutes, though the orally disintegrating Staxyn formulation produces a faster Cmax. The drug has a modest food interaction: a high-fat meal delays absorption by about 1 hour. Staxyn (10 mg ODT) should not be substituted dose-for-dose with Levitra tablets because bioavailability differs between formulations.

Prostaglandin E1: Alprostadil Specifics

Caverject (intracavernosal injection, 5 to 40 mcg) delivers alprostadil directly into the corpus cavernosum, producing rigidity in 5 to 20 minutes regardless of erotic stimulation. MUSE (medicated urethral system for erection, 125 to 1,000 mcg pellet) is absorbed transurethral, with onset in 5 to 10 minutes but substantially lower and less predictable bioavailability than injection. A 1996 NEJM trial by Linet et al. (N=1,511) found that 64.9% of men using the MUSE 1,000 mcg pellet had at least one successful intercourse attempt, compared with 18.6% on placebo. That gap is clinically meaningful, though injection formulations consistently outperform intraurethral delivery for rigidity.

Efficacy: What the Trial Data Show

Head-to-head data comparing vardenafil directly with alprostadil are limited, but both drugs have been evaluated rigorously in large controlled trials against placebo, and real-world registry data fill some of the gap.

Vardenafil Trial Outcomes

The International Index of Erectile Function (IIEF) has been the standard endpoint across vardenafil studies. In the key registration program, vardenafil 10 mg and 20 mg produced statistically significant improvements in IIEF erectile function domain scores compared with placebo across mild, moderate, and severe ED subgroups. Approximately 75 to 80% of men with mild-to-moderate ED achieve successful intercourse in controlled trials at 20 mg.

A 2003 real-world analysis by Porst et al. (Int J Impot Res, N=4,262) examined vardenafil 10 mg and 20 mg across diverse clinical subgroups including diabetics, men with hypertension, and those who had undergone radical prostatectomy. Diabetic men on vardenafil 20 mg showed an IIEF-EF domain score improvement of 6.4 points from baseline (P<0.001). Men with hypertension improved by 6.9 points. Post-prostatectomy response was lower but still statistically significant, reflecting partial preservation of cavernosal nerves in nerve-sparing procedures.

Alprostadil Trial Outcomes

The landmark Linet et al. NEJM trial (N=1,511) demonstrated MUSE 1,000 mcg produced successful intercourse in 64.9% versus 18.6% placebo (P<0.001) across 12 study sessions. Caverject injection at doses of 10 to 20 mcg routinely achieves erection in 70 to 85% of men, including those who have failed oral PDE5 inhibitors, across multiple real-world series.

Men with complete cavernous nerve disruption after non-nerve-sparing radical prostatectomy show minimal response to vardenafil but may retain 60 to 70% response rates with intracavernosal alprostadil, making injection therapy the preferred route in that population.

Where Each Drug Wins

Vardenafil outperforms in men with intact nitric-oxide signaling (mild-to-moderate vasculogenic or psychogenic ED, well-controlled diabetes). Alprostadil outperforms in neurogenic failure, severe arterial insufficiency, and confirmed PDE5 non-response. For men who have failed two or more PDE5 inhibitors at maximum dose and adequate trial duration, the AUA 2018 Erectile Dysfunction Guideline recommends second-line therapies including intracavernosal injection with alprostadil or combination vasoactive agents.

Side-Effect Profiles

The adverse-effect landscapes of these two drugs differ so substantially that tolerability often drives the final choice as much as efficacy does.

Vardenafil Side Effects

Vardenafil's systemic vasodilation produces the class-typical side effects of PDE5 inhibitors: flushing (11 to 13%), headache (15%), nasal congestion (9%), and dyspepsia (4%). Most of these are dose-dependent and resolve spontaneously.

More serious concerns include QTc prolongation. Vardenafil prolongs the QT interval modestly at therapeutic doses, and the prescribing information carries a specific warning against co-administration with Class 1A (quinidine, procainamide) or Class 3 (amiodarone, sotalol) antiarrhythmics. Co-administration with nitrates of any form (oral, transdermal, sublingual) is absolutely contraindicated due to the risk of severe, potentially fatal hypotension. Alpha-blocker co-use requires caution and at least a 6-hour separation between doses of tamsulosin 0.4 mg and vardenafil.

Alprostadil Side Effects

Alprostadil's side-effect profile is almost entirely local. Penile pain during or after injection is the most common adverse effect, reported in up to 37% of men in long-term use series. Prolonged erection (lasting more than 4 hours) occurs in 1 to 4% of cases with injection and is a urological emergency if it persists beyond 4 hours; early intervention is necessary to prevent permanent cavernosal fibrosis. With MUSE, the most common adverse effects are urethral burning (reported in 32 to 35% of MUSE users in the Linet trial) and minor urethral bleeding.

Systemic hypotension with alprostadil is rare at the doses used for Caverject injection but is more likely with MUSE due to systemic absorption. Alprostadil injection is contraindicated in men with sickle-cell anemia, multiple myeloma, leukemia, and penile anatomical deformities (Peyronie disease with severe curvature) that make injection hazardous.

Real-World Adherence and Discontinuation

Controlled trial data consistently overestimate real-world adherence. Understanding the gap matters for clinical decision-making.

Why Men Stop Vardenafil

Long-term adherence to oral PDE5 inhibitors is lower than trial data suggest. A primary driver of discontinuation is loss of efficacy over time, particularly in men with worsening cardiovascular risk factors or progressive neuropathy from diabetes. Unrealistic expectations, relationship factors, and cost (without insurance coverage, branded Levitra runs $60, $90 per pill, though generic vardenafil has dropped to $1, $3/dose) also contribute.

The AUA Guideline notes that patient education about the need for sexual stimulation, correct timing, and food interactions substantially improves response rates among men who initially report PDE5 "failure." A meaningful portion of apparent vardenafil non-responders are actually suboptimal users rather than true non-responders.

Why Men Stop Alprostadil

Injection therapy carries a high early dropout rate unrelated to efficacy. Needle anxiety, partner reluctance, and the preparation burden cause 30 to 50% of men to discontinue intracavernosal therapy within the first year in real-world series, even when the drug itself works. MUSE discontinuation is even higher, driven by urethral discomfort and inferior rigidity compared with injection.

A practical clinical framework used by the HealthRX medical team stratifies men into three groups before recommending alprostadil:

1. True PDE5 non-responders: Men who have used vardenafil 20 mg (or equivalent sildenafil 100 mg, tadalafil 20 mg) on at least four attempts with adequate stimulation, correct timing, and no food interference. These men merit alprostadil injection as second-line.
2. PDE5-contraindicated men: Men on nitrates or with severe cardiovascular instability for whom any PDE5 inhibitor is unsafe. Alprostadil injection is first-line in this group.
3. Partial PDE5 responders: Men who achieve partial tumescence but not sufficient rigidity for penetration. A combination injection of alprostadil plus phentolamine or papaverine (bimix or trimix) is often preferred over switching to MUSE.

Switching From Vardenafil to Alprostadil: Clinical Guidance

Switching is indicated when a man has genuinely failed oral therapy, not simply tried it once under suboptimal conditions.

Confirming True PDE5 Failure

Before switching, a prescriber should confirm the man has taken vardenafil 20 mg (the maximum approved oral dose) on at least four separate occasions, with sexual stimulation, 60 minutes after a light meal, without alcohol. Many men report "Levitra doesn't work" after one or two poorly timed attempts. Correct-use re-education resolves the apparent failure in a substantial subgroup.

If true failure is confirmed, checking serum testosterone is appropriate. Hypogonadism (total testosterone below 300 ng/dL by Endocrine Society criteria) blunts PDE5 response; testosterone replacement alone, or combined with vardenafil, can restore PDE5 efficacy before escalating to injection.

Starting Alprostadil After Vardenafil Failure

The transition to intracavernosal alprostadil should happen with an in-office dose titration. Most guidelines recommend starting at 2.5 mcg in neurogenic ED or 5 mcg in vasculogenic ED and titrating upward in the office until the patient achieves an erection adequate for intercourse lasting no more than 60 minutes. Sending a man home with Caverject without in-office titration is a patient-safety gap because the risk of priapism is dose-dependent and individual thresholds vary widely.

The man (and ideally his partner) should receive hands-on injection training from a clinical staff member. Proper injection technique reduces local side effects and improves long-term adherence.

Combining or Sequencing Alprostadil Formulations

Some men who tolerate Caverject injection poorly prefer MUSE as a less invasive option. MUSE is also useful as a bridge when a man runs out of injectable supplies or is traveling. Clinicians should counsel that MUSE's success rate is lower than injection, and that MUSE should not be used immediately after Caverject on the same occasion.

Drug Interactions and Contraindications

Vardenafil Drug Interactions

| Interacting Drug/Class | Interaction | Clinical Action | |---|---|---| | Organic nitrates (nitroglycerin, isosorbide) | Severe hypotension; potentially fatal | Absolute contraindication | | Alpha-blockers (tamsulosin, doxazosin) | Additive hypotension | Separate doses by 6 hours; use lowest vardenafil dose | | Strong CYP3A4 inhibitors (ketoconazole, ritonavir) | Increased vardenafil AUC up to 49-fold | Reduce dose to 2.5 mg; avoid with ritonavir | | Class 1A/3 antiarrhythmics | QTc prolongation | Contraindicated |

Alprostadil Drug Interactions

Alprostadil has fewer systemic drug interactions than vardenafil because local delivery minimizes systemic exposure with injection. Anticoagulants (warfarin, apixaban) raise the risk of injection-site hematoma and require careful patient counseling. Vasoactive agents used in combination (papaverine, phentolamine) increase the risk of priapism and should only be combined under physician supervision with a dose-reduced formulation.

Patient Selection: Who Should Get Which Drug

Good Candidates for Vardenafil First

Men with psychogenic or mild vasculogenic ED, normal testosterone, no contraindication to PDE5 inhibitors, and intact sacral reflex are the best candidates for vardenafil as the first oral agent. Men who prefer spontaneity (within the 4 to 5-hour window) and want to avoid injections are best served by trying the full range of oral PDE5 inhibitors before considering alprostadil.

Younger men with situational ED and performance anxiety often respond well to vardenafil 10 mg combined with brief psychosexual counseling. One small series reported that 78% of men with purely psychogenic ED responded to PDE5 inhibitors versus 56% in mixed-etiology ED, underscoring the importance of accurate diagnosis before prescribing.

Good Candidates for Alprostadil

Men with confirmed neurogenic ED after radical prostatectomy, pelvic radiation, or spinal cord injury are strong alprostadil candidates. Alprostadil also fits men who cannot use PDE5 inhibitors due to nitrate co-administration (for example, stable coronary artery disease managed with long-acting nitrates) or severe hepatic impairment that contraindicates vardenafil.

Older men with mixed severe vascular disease and diabetes who have failed two or more PDE5 inhibitors at maximum dose are the core real-world population driving intracavernosal alprostadil prescriptions. A review published in JAMA (2016) on treatment selection for erectile dysfunction concluded that PDE5 inhibitors are preferred as first-line, with intracavernosal therapies as established second-line options backed by decades of trial evidence.

Cost and Access

Generic vardenafil became available in the United States after the Levitra patent expired, dropping the per-dose cost to $1, $3 at major pharmacy benefit managers. Alprostadil has no inexpensive generic equivalent widely available; branded Caverject 10 mcg vials typically run $25, $80 per dose, and MUSE suppositories run $40, $80 per dose at retail pharmacies. Compounded trimix (alprostadil-phentolamine-papaverine) from 503B outsourcing facilities can reduce per-injection cost to $5, $15 and is widely used in men's sexual health telehealth practices, though compounded formulations are not FDA-approved and quality varies by pharmacy.

Insurance coverage for both drugs varies significantly by plan. Many commercial plans cover generic vardenafil at a low tier; intracavernosal alprostadil is often covered under a medical benefit (billed as a self-injected drug) rather than pharmacy benefit, requiring a separate prior authorization.

Monitoring and Follow-Up

Men starting vardenafil should be reassessed at 4 to 8 weeks to confirm correct use and evaluate response. Men starting alprostadil injection require an in-office titration visit, a 2-week follow-up call to assess technique and adverse effects, and a 3-month check-in to evaluate long-term adherence and detect fibrosis from repeated injection. Any erection lasting more than 4 hours after alprostadil injection requires immediate emergency evaluation.

Baseline cardiovascular evaluation is appropriate before starting either drug in men with uncontrolled hypertension, angina, or recent myocardial infarction within the past 90 days. The Princeton Consensus (3rd Panel) stratifies men into low-, intermediate-, and high-cardiac-risk categories and provides guidance on when to defer, evaluate, or proceed with sexual activity and ED pharmacotherapy.